Development Group’s (DG) mission focuses on better and faster process development of biopharmaceutical medicines. Formed in 2011, DG now has more than 700+ subject matter experts collaborating in teleconferences every month across 13 collaboration workstream topics. There are also three face-to-face meetings (currently virtual) throughout the year with subject matter experts and key opinion leaders collaborating on the key hot topics and...
Viewing related articles
BioPhorum and United States Pharmacopeia (USP) share a common direction – to accelerate biopharma innovation, quality and progress through collaboration. To this end, USP is engaging with industry to understand its pain points, its challenges and where there is the potential for new standards. “We have been looking at what additional standards we can develop that aren’t necessarily the traditional USP product-specific standards, but that would...
Oct 2018 | Development Group
This blinded survey was devised and completed by 11 companies, compares and explores the use of surfactants in biologic formulations. In total the responsants covered 59 different questions in such areas as, general use of surfactants, polysorbate raw material, polysorbate handling for GMP manufacture, polysorbate degradation, specifications, poloxamer and health authorities interactions.
A further two benchmark surveys have been developed by the team. Surfactants in Biological Formulations covers the use of surfactants in biologics formulation.
Feb 2018 | Development Group
To gain a better understanding of current industry approaches for establishing biopharmaceutical drug product (DP) robustness, the BPDG-Formulation Workstream conducted an intercompany collaboration exercise, which included a benchmarking survey and extensive group discussions around the scope, design, and execution of robustness studies. The results of this industry collaboration revealed several key common themes: (1) overall DP robustness is defined by both the formulation and the manufacturing process robustness; (2) robustness integrates the principles of quality by design (QbD); (3) DP robustness is an important factor in setting critical quality attribute control strategies and commercial specifications; (4) most companies employ robustness studies, along with prior knowledge, risk assessments, and statistics, to develop the DP design space; (5) studies are tailored to commercial development needs and the practices of each company. Three case studies further illustrate how a robustness study design for a biopharmaceutical DP balances experimental complexity, statistical power, scientific understanding, and risk assessment to provide the desired product and process knowledge. The team discusses identified industry challenges with regard to biopharmaceutical DP robustness and presents some recommendations for best practices.
Formulation: An intercompany perspective on biopharmaceutical drug product robustness studies: PRESENTATION
Aug 2017 | Development Group
As a companion to the paper ‘An inter-company perspective on biopharmaceutical drug product robustness studies’, you can find here a poster and presentation that have been presented at five conferences between August 2017 and September 2019.
Mar 2017 | Development Group
High concentration formulations can be challenging to develop and there was interest in the Formulations workstream in the comparative approaches taken towards stability testing, syringability testing, the approach to subvisible particles, how solubility, aggregation, and particle formation issues are studied, the challenges associated with high viscosity formulations in PFS, the use of needle-free delivery systems or large volume injectors, concentration-driven formulation challenges, approach to unstable biopharmaceuticals, how acceptable opalescence is defined, how Gibbs-Donnan and excluded volume effects for excipients are accounted for, among other more detailed questions